GeneCentric Therapeutics

GeneCentric develops liquid biopsy technology and software that extracts gene expression data from circulating tumor DNA sequencing, enabling biomarker measurements such as ER status, HER2 expression, and molecular subtypes for cancer diagnostics. The company partners with biopharma, diagnostics companies, and commercial labs to integrate its ExpressCT™ fragmentomics technology into genomic profiling workflows.